Dupilumab Reduces Exacerbations And Improves Lung Function In Children (6-11 Years) With Moderate-To-Severe Asthma And High Eosinophils
Jackson D, Hamelmann E, Roberts G, Bacharier L, Altincatal A, Gall R, Ledanois O, Jacob-Nara J, Radwan A, Rowe P, Deniz Y (2023)
Journal of Allergy and Clinical Immunology 151(2): AB194.
Kurzbeitrag Konferenz / Poster
| Veröffentlicht | Englisch
Download
Es wurden keine Dateien hochgeladen. Nur Publikationsnachweis!
Autor*in
Jackson, Daniel;
Hamelmann, EckardUniBi;
Roberts, Graham;
Bacharier, Leonard;
Altincatal, Arman;
Gall, Rebecca;
Ledanois, Olivier;
Jacob-Nara, Juby;
Radwan, Amr;
Rowe, Paul;
Deniz, Yamo
Erscheinungsjahr
2023
Serien- oder Zeitschriftentitel
Journal of Allergy and Clinical Immunology
Band
151
Ausgabe
2
Seite(n)
AB194
ISSN
0091-6749
eISSN
1097-6825
Page URI
https://pub.uni-bielefeld.de/record/2980012
Zitieren
Jackson D, Hamelmann E, Roberts G, et al. Dupilumab Reduces Exacerbations And Improves Lung Function In Children (6-11 Years) With Moderate-To-Severe Asthma And High Eosinophils. Journal of Allergy and Clinical Immunology. 2023;151(2):AB194.
Jackson, D., Hamelmann, E., Roberts, G., Bacharier, L., Altincatal, A., Gall, R., Ledanois, O., et al. (2023). Dupilumab Reduces Exacerbations And Improves Lung Function In Children (6-11 Years) With Moderate-To-Severe Asthma And High Eosinophils. Journal of Allergy and Clinical Immunology, 151(2), AB194. https://doi.org/10.1016/j.jaci.2022.12.608
Jackson, Daniel, Hamelmann, Eckard, Roberts, Graham, Bacharier, Leonard, Altincatal, Arman, Gall, Rebecca, Ledanois, Olivier, et al. 2023. “Dupilumab Reduces Exacerbations And Improves Lung Function In Children (6-11 Years) With Moderate-To-Severe Asthma And High Eosinophils”, Journal of Allergy and Clinical Immunology, 151 (2): AB194.
Jackson, D., Hamelmann, E., Roberts, G., Bacharier, L., Altincatal, A., Gall, R., Ledanois, O., Jacob-Nara, J., Radwan, A., Rowe, P., et al. (2023). Dupilumab Reduces Exacerbations And Improves Lung Function In Children (6-11 Years) With Moderate-To-Severe Asthma And High Eosinophils. Journal of Allergy and Clinical Immunology 151, AB194.
Jackson, D., et al., 2023. Dupilumab Reduces Exacerbations And Improves Lung Function In Children (6-11 Years) With Moderate-To-Severe Asthma And High Eosinophils. Journal of Allergy and Clinical Immunology, 151(2), p AB194.
D. Jackson, et al., “Dupilumab Reduces Exacerbations And Improves Lung Function In Children (6-11 Years) With Moderate-To-Severe Asthma And High Eosinophils”, Journal of Allergy and Clinical Immunology, vol. 151, 2023, pp. AB194.
Jackson, D., Hamelmann, E., Roberts, G., Bacharier, L., Altincatal, A., Gall, R., Ledanois, O., Jacob-Nara, J., Radwan, A., Rowe, P., Deniz, Y.: Dupilumab Reduces Exacerbations And Improves Lung Function In Children (6-11 Years) With Moderate-To-Severe Asthma And High Eosinophils. Journal of Allergy and Clinical Immunology. 151, AB194 (2023).
Jackson, Daniel, Hamelmann, Eckard, Roberts, Graham, Bacharier, Leonard, Altincatal, Arman, Gall, Rebecca, Ledanois, Olivier, Jacob-Nara, Juby, Radwan, Amr, Rowe, Paul, and Deniz, Yamo. “Dupilumab Reduces Exacerbations And Improves Lung Function In Children (6-11 Years) With Moderate-To-Severe Asthma And High Eosinophils”. Journal of Allergy and Clinical Immunology 151.2 (2023): AB194.
Export
Markieren/ Markierung löschen
Markierte Publikationen
Web of Science
Dieser Datensatz im Web of Science®Suchen in
Google Scholar